

Selected full papers (1968-2022)

1. **Papp JGy**, Szekeres L: Analysis of the mechanism of adrenergic actions on ventricular vulnerability.

Eur. J. Pharmacol. 3:15-26, 1968.

2. **Papp JGy**, Szekeres L: The arrhythmogenic action of sympathomimetic amines.

Eur. J. Pharmacol. 3:4-14, 1968.

3. **Papp JGy**, Vaughan Williams EM: The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity.

Br. J. Pharmacol. 37:380-390, 1969.

4. **Papp JGy**, Vaughan Williams EM: A comparison of the anti-arrhythmic actions of I.C.I. 50172 and (-)propranolol and their effects on intracellular cardiac action potentials and other features of cardiac function.

Br.J.Pharmacol. 37:391-399, 1969.

5. Freedberg AS, **Papp JGy**, Vaughan Williams EM: The effect of altered thyroid state on atrial intracellular potentials.

J. Physiol. (London) 207:357-369, 1970.

6. **Papp JGy**: Autonomic responses and neurohumoral control in the human early antenatal heart.

Basic Res. Cardiol. 83:2-9, 1988

7. Udvary É, **Papp JGy**, Végh Á: Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.

Br. J. Pharmacol. 114:656-661, 1995.

8. Édes I., Kiss É, Kitada Y, Powers FM, **Papp JGy**, Kranias EG, Solaro RJ: Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca²⁺ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.

Circ. Res. 77:107-113, 1995

9. **Papp JGy**, Németh M, Krassósi I, Mester L, Hála O, Varró A: Differential electrophysiological effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle.

J. Cardiovasc. Pharmacol. Therapeut. 1:287-296, 1996.

10. Baczkó I., Leprán I., **Papp JGy**: KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.

Eur.J. Pharmacol. 324:77-83, 1997.

11. **Papp JGy**: Positive inotropy by calcium sensitization - an evolving approach for the treatment of end-stage heart failure.

Am.J.Cardiol. 83:1(I)-3(I), 1999.

12. Baláti B, Varró A, **Papp JGy**: Pharmacological modification of the dispersion of repolarization in the heart: importance of the M cells.

Cardiovasc. Drugs Ther. 13:491-505, 1999.

13. Kis A, Végh Á, **Papp JGy**, Parratt JR: Pacing induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase.
Br.J. Pharmacol. 127:1545-1555, 1999
14. Varró A, Baláti B, Iost N, Takács J, Virág L, Lathrop DA, Lengyel Cs, Tálosi L, **Papp JGy**: The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre.
J. Physiol. (London) 523:67-81, 2000.
15. Virág L, Iost N, Opincariu M, Szécsi J, Bogáts G, Szenohradszky P, Varró A, **Papp JGy**: The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes.
Cardiovasc. Res. 49:790-797, 2001.
16. Csete K, Barzó P, Bodosi M, **Papp JGy**: Influence of nitrovasodilators and cyclooxygenase inhibitors on cerebral vasoreactivity in conscious rabbits.
Eur. J. Pharmacol. 412:301-309, 2001.
17. Opincariu M, Varró A, Iost N, Virág L, Hála O, Szolnoki J, Szécsi J, Bogáts G, Szenohradszky P, Mátyus P, **Papp JGy**: The cellular electrophysiological effect of a new amiodarone-like antiarrhythmic drug GYKI 16638 in undiseased human ventricular muscle: comparison with sotalol and mexiletine.
Current Medicinal Chemistry 9:41-46, 2002.
18. Biliczki P, Virág L, Iost N, **Papp JGy**, Varró A: Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.
Br. J. Pharmacol. 137:361-368, 2002.
19. Zicha S, Moss I, Varró A, **Papp JGy**, Dumaine R, Antzelevich C, Nattel S : Molecular basis of species-specific expression of repolarizing K⁺ currents in the heart.
Am.J. Physiol. 285:H1641-1649, 2003.
20. **Papp JGy**, Singh BN : Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.
J. Cardiovasc. Pharmacol. Ther. 8S-I : S3, 2003
21. Leprán I, **Papp JGy** : Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary occlusion in conscious rats.
Eur.J. Pharmacol. 464:171-176, 2003
22. Mátyus P, Varga I, Reggeti T, Simay A, Kállai N, Károlyházy L, Kocsis Á, Pémes I, **Papp JGy** : Novel antiarrhythmic compounds with combined class IB and class IIIb mode of action.
Current Medicinal Chemistry 11:61-69, 2004.
23. Nagy ZsA, Virág L, Tóth A, Biliczki P, Acsai K, Bányász T, Nánási P, **Papp JGy**, Varró A : Selective inhibition of sodium-calcium exchanger by SEA-0400 decreases early and delayed afterdepolarization in canine heart.
Br. J. Pharmacol. 143:827-831, 2004.
24. Lengyel Cs, Dézsi L, Biliczki P, Horváth Cs, Virág L, Jost N, Németh M, Tálosi L, **Papp JGy**, Varró A : Effect of a neuroprotective drug, eliprodil on cardiac repolarization : importance of the decreased repolarization reserve in the development of proarrhythmic risk.
Br. J. Pharmacol. 143:152-158, 2004.

25. Höhn J, Pataricza J, Petri A, Gábor K, Balogh Á, Varró A, **Papp JGy**: Levosimendan interacts with potassium channel blockers in human saphenous vein.
Pharmacol. Toxicol. **94**:271-273, 2004.
26. Jost N, Virág L, Hála O, Thormählen D, **Papp JGy** : Effects of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes.
Current Medicinal Chemistry **11**:3219-3228, 2004.
27. Biliczki P, Acsai K, Virág L, Tálósi L, Jost N, Biliczki A, **Papp JGy**, Varró A: Cellular electrophysiological effect of terikalant in the dog heart.
Eur.J.Pharmacol. **510**:161-166, 2005.
28. Borbély A, Tóth A, Édes I, Vaszi M, Virág L, Szűts V, **Papp JGy**, Varró A, Paulus WJ, Van der Velden J, Stienen GJM, Papp Z: Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells.
Cardiovasc.Res. **67**:225-233, 2005.
29. Jost N, Virág L, Bitay M, Takács J, Lengyel C, Biliczki P, Nagy Z, Bogáts G, Lathrop DA, **Papp JGy**, Varró A: Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
Circulation **112**:1392-1399, 2005.
30. Márton Z, Pataricza J, Krassói I, Varró A, **Papp JGy** : NEP inhibitors enhance C-type natriuretic peptide-induced relaxation in porcine isolated coronary artery.
Vasc. Pharmacol. **43**:207-12, 2005.
31. Ördög B, Brutyó E, Puskás LG, **Papp JGy**, Varró A, Szabad J, Boldogkői Zs: Gene expression profiling of human cardiac potassium and sodium channels.
Int.J.Cardiol. **111**:386-393, 2006.
32. Varró A, **Papp JGy**: Low penetrance, subclinical LQTS: concealed LQTS or silent LQTS?
Cardiovasc.Res. **70**:404-406, 2006.
33. Pataricza J, Szolnoky J, Krassói I, Hegedüs Z, Kun A, Varró A, **Papp JGy**: Vasorelaxing effect of levosimendan against 5-hydroxy triptamine-induced contractions in isolated human conduit bypass grafts.
J.Pharm.Pharmacol. **58**: 1107-1112, 2006.
34. **Papp JGy**, Pollesello P, Varró A, Végh Á: Effect of levosimendan and milrinone on regional myocardial ischemia- and reperfusion-induced arrhythmias in dogs.
J.Cardiovasc.Pharmacol.Therapeut. **11**:129-135, 2006.
35. **Papp JGy**, Pollesello P, Varró A, Végh Á : The effect of levosimendan during long-term amiodarone-treatment in dogs.
Basic & Clinical Pharmacology and Toxicology **99**:27-32, 2006.
36. Leprán I, Pollesello P, Vajda Sz, Varró A, **Papp JGy**: Preconditioning effects of levosimendan in a rabbit cardiac ischaemia-reperfusion model.
J.Cardiovasc.Pharmacol. **48**:148-152, 2006.
37. Molnár A, Tóth A, Bagi Z, Papp Z, Édes I, Vaszi M, Galajda Z, **Papp JGy**, Varró A, Szűts V, Gerő D, Lazca Z, Szabó C : Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure
Mol.Med. **12**:143-152, 2006.

38. Farkas AS, Acsai K, Nagy N, Tóth A, Dési L, Orosz S, Forster T, Csanády M, **Papp JGy**, Varró A, Farkas A: Importance of extracardiac α -adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts.
Eur.J. Pharmacol. **537:118-125, 2006.**
39. Jost N, **Papp JGy**, Varró A: Slow delayed rectifier potassium current (IKs) and the repolarization reserve.
Annals Noninvas. Electrocardiol. **12:64-78, 2007.**
40. Lengyel Cs, Virág L, Bíró T, Jost N, Magyar J, Biliczki P, Kocsis E, Skoumal R, Nánási PP, Tóth M, Kecskeméti V, **Papp JGy**, Varró A: Diabetes mellitus attenuates the repolarization reserve in mammalian heart.
Cardiovasc.Res. **73:512-520, 2007.**
41. Sas K, Csete K, Vezekényi Z, Sztricha L, Vécsei L, **Papp JGy**: Effect of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Acta Physiol. Hung. **94:167-177, 2007.**
42. Lengyel Cs, Varró A, Tábóri K, **Papp JGy**, Baczkó I: Combined pharmacologic block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes.
Br. J. Pharmacol. **151:941-951, 2007.**
43. Acsai K, Kun A, Farkas AS, Fülöp F, Nagy N, Balázs M, Szentandrassy N, Nánási PP, **Papp JGy**, Varró A, Tóth A: Effect of partial blockade of the Na⁺/Ca²⁺-exchanger on Ca²⁺ handling in isolated rat ventricular myocytes.
Eur. J. Pharmacol. **576:1-6, 2007.**
44. Tóth-Molnár E, Venglovecz V, Ózsvári B, Rakonczay Z, Varró A, **Papp JGy**, Tóth A, Lonovics I, Takáts T, Ignáth I, Iványi B, Hegyi P: A new experimental method to study the acid/base transporters and their regulation in lacrimal gland ductal epithelia.
Invest. Ophthalm. & Visual Sci. **48:3746-3755, 2007.**
45. Lengyel Cs, Virág L, Kovács PP, Kristóf A, Pacher P, Kocsis E, Koltai ZsM, Nánási PP, Tóth M, Kecskeméti V, **Papp JGy**, Varró A, Jost N: Role of slow delayed K⁺-current in QT prolongation in the alloxan-induced diabetic rabbit heart.
Acta Physiol. (Scand.) **192:359-368, 2008.**
46. Farkas AS, Acsai K, Nagy N, Tóth A, Fülöp F, Seprényi G, Birinyi P, Nánási PP, Forster T, Csanády M, **Papp JGy**, Varró A, Farkas A : Na⁺/Ca²⁺ exchanger inhibition exerts positive inotropic effect in the rat heart, but fails to influence the contractility of the rabbit heart.
Br.J.Pharmacol. **154:93-104, 2008.**
47. Birinyi P, Tóth A, Jóna I, Acsai K, Almássy J, Nagy N, Prorok J, Gherasim I, Papp Z, Hertelendy Z, Szentandrassy M, Bányász T, Fülöp F, **Papp JGy**, Varró A, Nánási PP, Magyar J: The Na⁺/Ca²⁺ exchange blocker SEA0400 fails to enhance cytosolic Ca²⁺ transient and contractility in canine ventricular cardiomyocytes.
Cardiovasc. Res. **78:476-484, 2008.**
48. Vincze D, Farkas AS, Rudas L, Makra P, Csik N, Leprán I, Forster T, Csanády M, **Papp JGy**, Varró A, Farkas A: Relevance of anaesthesia for dofetilide-induced torsades de pointes in a 1-adrenoceptor-stimulated rabbits.
Br.J. Pharmacol. **153: 75-89, 2008.**
49. **Papp Gy**, VarróA, Baczkó I: Genomics of cardiomyocyte signalling to treat and prevent heart failure ("EugeneHeart" Project).
Fókusz **3:29-30, 2008.**

50. Kun A, Király I, Pataricza J, Márton Z, Krassói I, Varró A, Simonsen U, **Papp JGy**, Pajor L : C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries. **J.Sex.Med. 5:1114-1125, 2008.**

51. Pataricza J, Márton Z, Lengyel Cs, Tóth M, **Papp JGy**, Varró A, Kun A : Potassium channels sensitive to combination of charybdotoxin and apamin regulate the tone of diabetic isolated coronary arteries. **Acta Physiol. (Scand.) 194:35-43, 2008.**

52. Koini EN, Papazafiri P, Vassilopoulos A, Koufaki M, Horváth Z, Koncz I, Virág L, **Papp JGy**, Varró A, Calogeropoulou T : 5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury. **J Med Chem. 52:2328-2340, 2009.**

53. Farkas AS, Makra P, Csík N, Orosz Sz, Shattock MJ, Fülöp F, Forster T, Csanády M, **Papp JGy**, Varró A, Farkas A : The role of the Na⁽⁺⁾/Ca⁽²⁺⁾ exchanger, I(Na) and I(CaLM) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts. **Br.J. Pharmacol. 156:920-932, 2009.**

54. Virág L, Acsai K, Hála O, Zaza A, Bitay M, Bogáts G, **Papp JGy**, Varró A: Self-augmentation of the lengthening of repolarization is related to the shape of the cardiac action potential: implications for reverse rate dependency. **Br.J. Pharmacol. 156:1076-1084, 2009.**

55. Szolnok J, Ambrus N, Szabó-Biczók A, Bogáts G, **Papp JGy**, Varró A, Pataricza J : Biseko colloidal solution diminishes the vasoreactivity of human isolated radial arteries. **Eur J Cardiothorac Surg. 36:143-147, 2009.**

56. Prorok J, Kovács PP, Kristóf A, Nagy N, Tombácz D, Tóth JS, Ördögh B, Jost N, Virág L, **Papp JGy**, Varró A, Tóth A, Boldogkői Zs: Herpes-virus mediated delivery of genetically encoded fluorescent Ca²⁺ sensor to canine cardiomyocytes. **Journal of Biomedicine and Biotechnology 2009:1-12, Paper 361795,2009.**

57. Nagy N, Szűts V, Horváth Z, Seprényi Gy, Farkas AS, Acsai K, Prorok J, Bitay M, Kun A, Pataricza J, **Papp JGy**, Nánási PP, Varró A, Tóth A: Does small conductance potassium channel contribute to cardiac repolarization? **Journal of Molecular and Cellular Cardiology 47:657-663, 2009.**

58. Pataricza J, Krassói I, Ambrus N, Bitay M, Varró A, **Papp JGy**: Interspecies differences and extracellular calcium dependence in the vasorelaxing effect of cromakalim in isolated human, porcine and canine coronary arteries. **Journal of Cardiovascular Pharmacology and Therapeutics 15:289-295, 2010.**

59. Farkas AS, Rudas L, Makra P, Csík N, Leprán I, Forster T, Csanády M. **Papp JGy**, Varró A, Farkas A: Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated, anaesthetized rabbits. **British Journal of Pharmacology 161:1477-1495, 2010.**

60. Virág L, Jost N, Papp R, Koncz I, Kristof A, Kohajda Zs, Harmati G, Carbonell-Pascual B, Ferrero JM(Jr), **Papp JGy**, Nánási PP, Varró A: Analysis of the contribution of I_{to} to repolarization in canine ventricular myocardium. **British Journal of Pharmacology 164:93-105, 2011.**

61. Koncz I, Szél T, Jaeger K, Baczkó I, Cerbai E, Romanelli MN, **Papp JGy**, Varró A: Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutic targets.

Current Medicinal Chemistry 18:3662-3674, 2011.

62. Szél T, Koncz I, Jost N, Baczkó I, Husti Z, Virág L, Bussek A, Wetter E, Ravens U, **Papp JGy**, Varró A: Class I/B antiarrhythmic property of rannolazine, a novel antianginal agent, in dog and human cardiac preparations.

European Journal of Pharmacology 662:31-39, 2011.

63. Lengyel Cs, Orosz A, Hegyi P, Komka Zs, Udvardy A, Bosnyák E, Trájer E, Pavlik G, Tóth M, Wittmann T, **Papp JGy**, Varró A, Baczkó I: Increased short-term variability of the QT interval in professional soccer players: possible implications for arrhythmia prediction.

Plos one 6:e18751, 2011.

64. Koncz I, Szél T, Bitay M, Cerbai E, Jaeger K, Fülöp F, Jost N, Virág L, Orvos P, Tálosi L, Kristóf A, Baczkó I, **Papp JGy**, Varró A: Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions.

European Journal of Pharmacology 668:419-426, 2011.

65. Ambrus N, Szolnoky J, Pollesello P, Kun A, Varró A, **Papp JGy**, Pataricza J: Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan.

Basic & Clinical Pharmacology & Toxicology 110:269-274, 2012.

66. Kristóf A, Husti Z, Koncz I, Kohajda Zs, Szél T, Juhász V, Biliczki P, Jost N, Baczkó I, **Papp JGy**, Varró A, Virág L: Diclofenac Prolongs Repolarization in Ventricular Muscle with impaired Repolarization Reserve.

Plose One 7:e53255, 2012.

67. Szüts V, Ménesi D, Varga-Orvos Z, Zvara Á, Houshmand N, Bitay M, Bogáts G, Virág L, Baczkó I, Szalontai B, Geramipoor A, Cotella D, Wettwer E, Ravens U, Deák F, Puskás LG, **Papp JGy**, Kiss I, Varró A, Jost N: Altered expression of genes for Kir ion channels in dilated cardiomyopathy.

Can. J. Physiol. Pharm. 91:648-656, 2013.

68. Király I, Pataricza J, Bajory Z, Simonsen U, Varró A, **Papp JGy**, Pajor L, Kun A: Involvement of large conductance Ca²⁺-activated K⁺ channels in both nitric oxide and endothelium derived hyperpolarization-type relaxation in human penile small arteries.

Basic & Clin. Pharm & Toxicol. 113:19-24, 2013.

69. Pataricza J, Ambrus N, Pollesello P, Levijoki J, Kun A, Varró A, **Papp JGy**: Inhibition of thrombin-induced platelet aggregation by levosimendan is modified by small changes in albumin concentration in vitro.

Experimental and Clinical Cardiology 19: 1-4, 2013.

70. Nagy N, Acsai K, Kormos A, Sebők Zs, Farkas AS, Jost N, Nánási PP, **Papp JGy**, Varró A, Tóth A: Ca²⁺ -induced augmentation of the inward rectifier potassium current (IK1) in canine and human ventricular myocardium.

Pflügers Archiv - European Journal of Pharmacology 465: 1621-1635, 2013.

71. Jost N, Nagy N, Corici C, Kohajda Zs, Horváth A, Acsai K, Biliczki P, Levijoki J, Pollesello P, Koskelainen T, Otsomaa L, Tóth A, **Papp JGy**, Varró A, Virág L: ORM-10103, a novel specific inhibitor of the sodium/calcium exchanger, decreases early and delayed afterdepolarization in the canine heart.

British Journal of Pharmacology 170: 768-778, 2013.

72. Jost N, Virág L, Comtois P, Ördög B, Szűts V, Seprényi Gy, Bitay M, Kohajda Zs, Konec I, Nagy N, Szél T, Magyar J, Kovács M, Puskás LG, Lengyel Cs, Wettwer E, Ravens U, Nánási PP, **Papp JGy**, Varró A, Nattel S: Ionic mechanisms limiting cardiac repolarization-reserve in humans compared to dogs.

J. Physiol. (London) 591: 4189-4206, 2013.

73. Kormos A, Nagy N, Acsai K, Vaczi K, Agoston S, Pollesello P, Levijoki J, Szentandrassy N, **Papp JGy**, Varró A, Tóth A: Efficacy of selective NCX inhibition by ORM-10103 during simulated ischaemia/reperfusion.

European Journal of Pharmacology 740: 539-551, 2014.

74. Kun A, Seprényi Gy, Varró A, **Papp JGy**, Pataricza J: Neurogenic Contraction Induced by the Antiarrhythmic Compound, AVE 0118, in Rat Small Mesenteric Arteries.

Basic & Clinical Pharmacology & Toxicology 115: 315-320, 2014.

75. Nagy N, Kormos A, Kohajda Z, Szebeni A, Szepesi J, Pollesello P, Levijoki J, Acsai K, Virág L, Nánási PP, **Papp JGy**, Varró A, Tóth A: Selective Na/Ca exchanger inhibition prevents Ca overload induced triggered arrhythmias.

British Journal of Pharmacology 171: (24) 5665-5681, 2014.

76. Orosz S, Sarusi A, Csík N, **Papp JGy**, Varró A, Farkas S, Forster T, Farkas AS, Farkas A: The assessment of efficacy of proarrhythmia biomarkers in isolated rabbit hearts with attenuated repolarization reserve.

Journal of Cardiovascular Pharmacology 64: 266-276, 2014.

77. Sarusi A, Rárosi F, Szűcs M, Csík N, Farkas AS, **Papp JGy**, Varró A, Forster T, Curtis MJ, Farkas A : Absolute beat-to-beat variability and instability parameters of ECG intervals: biomarkers for predicting ischaemia-induced ventricular fibrillation.

British Journal of Pharmacology 171: 1772-1782, 2014.

78. Orosz A, Csajbok E, Czekus C, Gavaller H, Magony S, Valkusz Z, Varkonyi TT, Nemes A, Baczko I, Forster T, Wittmann T, **Papp JGy**, Varro A, Lengyel C: Increased Short-Term Beat-To-Beat Variability of QT Interval in Patiens with Acromegaly.

Plose one 10:(4) p. e0125639, 2015.

79. Szepesi J, Acsai K, Sebok Z, Prorok J, Pollesello P, Levijoki J, **Papp JGy**, Varro A, Toth A : Comparison of the efficiency of Na⁺/Ca²⁺ exchanger or Na⁺/H⁺ exchanger inhibition and their combination in reducing coronary reperfusion-induced arrhythmias.

Journal of Physiology and Pharmacology 66:(2) pp. 215-226, 2015

80. Kui P, Orosz S, Takács H, Sarusi A, Csík N, Rárosi F, Csekő C, Varró A, **Papp JGy**, Forster T, Farkas AS, Farkas A: New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.

J Pharmacol Toxicol Methods 80:26-34, 2016.

81. Nagy L, Pollesello P, Haikala H, Végh Á, Sorsa T, Levijoki J, Szilágyi S, Édes I, Tóth A, Papp Z, **Papp JGy**: ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy.

Eur J Pharmacol 775:120-129, 2016.

82. Pollesello P, Papp Z, **Papp JGy**: Calcium sensitizers: What have we learned over the last 25 years?

Int J Cardiol. 203:543-548, 2016.

83. Takács H, Kui P, Farkas AS, Sarusi A, Forster T, **Papp JGy**, Varró A, Curtis MJ, Shattock MJ, Farkas A: Ventricular cycle length irregularity affects the correlation between ventricular rate and coronary flow in isolated, Langendorff perfused guinea pig hearts.

J Pharmacol Toxicol Methods. 77:45-52, 2016.

84. Papp H, Sarusi A, Farkas AS, Takács H, Kui P, Vincze P, Iványi E, Varró A, **Papp JGy**, Forster T, Farkas A: Hyperventilation assists proarrhythmia development during delayed repolarization in clofilium-treated anaesthetized, mechanically ventilated rabbit.

Journal of Physiology and Pharmacology 67:(5) pp. 731-737, 2016.

85. Gurabi Z, Patocskaï B, Györe B, Virág L, Mátyus P, **Papp JGy**, Varró A, Koncz I: Different electrophysiological effects of the levo- and dextro-rotatory isomers of mexiletine in isolated rabbit cardiac muscle.

Canadian Journal of Physiology and Pharmacology. 95:830-836, 2017.

86. Hegyi B, Bossuyt J, Griffiths LG, Shimkunas R, Coulibaly Z, Jian Z, Grimsrud KN, Sondergaard CS, Ginsburg KS, Chiamvimonvat N, Belardinelli L, Varró A, **Papp JGy**, Pollesello P, Levijoki J, Izu LT, Boyd WD, Bányász T, Bers DM, Chen-Izu Y: Complex electrophysiological remodeling in postinfarction ischemic heart failure.

Proceedings of the National Academy of Sciences of the United States of America 115:E3036-E3044, 2018.

87. Oravecz K, Kormos A, Gruber A, Márton Z, Kohajda Z, Mirzaei L, Jost N, Levijoki J, Pollesello P, Koskelainen T, Otsomaa L, Tóth A, **Papp JGy**, Nánási PP, Antoons G, Varró A, Acsai K, Nagy N.: Inotropic effect of NCX inhibition depends on the relative activity of the reverse NCX assessed by a novel inhibitor ORM-10962 on canine ventricular myocytes.

European Journal of Pharmacology 818:278-286, 2018.

88. Polyák A, Kui P, Morvay N, Leprán I, Ágoston G, Varga A, Nagy N, Baczkó I, Farkas A, **Papp JG**, Varró A, Farkas AS. Long-term endurance training-induced cardiac adaptation in new rabbit and dog animal models of the human athlete's heart.

Rev Cardiovasc Med. 19: 135-142, .2018.

89. Márton Z, Pataricza J, Pollesello P, Varró A, **Papp JG**. The novel inodilator ORM-3819 relaxes isolated porcine coronary arteries: role of voltage-gated potassium channels activation.

J Cardiovasc Pharmacol. 74:218-224, 2019.

90. Regev A, Takacs H, Farkas AS, Rarosi F, Polyak A, Papp H, Ivany E, **Papp JGy**, Varró A, Farkas A. Application of ventricular tachyarrhythmia definitions of the updated Lambeth Conventions provides incompatibility with earlier results, masks antifibrillatory activity and reduces inter-observer agreement.

J. Physiol. Pharmacol 70: 37-49, 2019.

91. Gazdag P, Oravecz K, Acsai K, Demeter-Haludka V, Ördög B, Szlovák J, Kohajda Zs, Polyák A, Barta BA, Oláh A, Radovits T, Merkely B, **Papp JGy**, Baczkó I, Varró A, Nagy N, Prorok J. Increased Ca²⁺ content of the sarcoplasmic reticulum provides arrhythmogenic trigger source in swimming-induced rat athlete's heart model

Scientific Reports 10: 19596, 2020.

92. Kohajda Zs, Tóth N, Szlovák J, Loewe A, Bitay G, Gazdag P, Prorok J, Jost N, Levijoki J, Pollesello P, **Papp JGy**, Varró A, Nagy N. Novel Na⁺/Ca²⁺ Exchanger Inhibitor ORM-10962 Supports Coupled Function of Funny-Current and Na⁺/Ca²⁺ Exchanger in Pacemaking of Rabbit Sinus Node Tissue

Frontiers in Pharmacol. 10: Art.No:1632, 2020.

93. Otsomaa L, Levijoki J, Wohlfahrt G, Chapman H, Koivisto AP, Syrjänen K, Koskelainen T, Peltokorpi S, Finckenberg P, Heikkilä A, Abi-Gerges N, Ghetti A, Miller PE, Page G, Mervaala E, Nagy N, Kohajda Zs, Jost N, Virág L, Varró A, **Papp JGy**. Discovery and characterization of ORM-11372, a unique and positively inotropic sodium-calcium exchanger/inhibitor.

Brit. J. Pharmacol. 177: 5534-5554, 2020.

94. Papp Z., Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LMA, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, **Papp JGy**, Parissis J, Parkhomenko A, Pöder P, Pözl G, Reinecke A, et al. Corresponding author Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

J. Cardiovasc. Pharmacol. 76: 4-22, 2020.

95. Magyar T, Árpádfy-Lovas T, Pászti B, Tóth N, Szlovák J, Gazdag P, Kohajda Zs, Gyökeres A, Györe B, Gurabi Zs, Jost N, Virág L, **Papp JGy**, Nagy N, Koncz I. Muscarinic agonists inhibit the ATP-dependent potassium current and suppress the ventricle-Purkinje action potential dispersion

Can J Physiol Pharmacol 99: 247-253, 2021.

96. Tóth, N, Szlovák J, Kohajda Zs, Bitay G, Veress R, Horváth B, **Papp JGy**, Varró A, Nagy N. The development of L-type Ca²⁺ current mediated alternans does not depend on the restitution slope in canine ventricular myocardium

Scientific Reports 11: 16652 , 2021.

97. Szlovák J, Tomek J, Zhou X, Tóth N, Veress R, Horváth B, Szentandrassy N, Levijoki J, **Papp JGy**, Herring N, et al. Blockade of sodium-calcium exchanger via ORM-10962 attenuates cardiac alternans

J of Mol. Cell. Card. 153: 11-122, 2021

98. Tóth N, Loewe A, Szlovák J, Kohajda Zs, Bitay G, Levijoki J, **Papp JGy**, Varró A, Nagy N.: The reverse mode of the Na⁺/Ca²⁺ exchanger contributes to the pacemaker mechanism in rabbit sinus node cells.

Scientific reports 12 Paper: 21830, 16 p. 2022.

99. Kui P, Polyák A, Morvay N, Tiszlavicz L, Nagy N, Ördög B, Takács H, Leprán I, Farkas A, **Papp JGy**., Jost N, Varró A, Baczkó I, Farkas AS. Long-Term Endurance Exercise Training Alters Repolarization in a New Rabbit Athlete's Heart Model

Physiol. 12: 741317, 2022.